SV Bio's process is fully computerized and automated, allowing for clinically actionable genome interpretation in a matter of minutes rather than weeks. While genome sequencing is gaining popularity as the cost continues to drop, the volume of data that results remains an issue in terms of managing, interpreting and making use of it across the board. SV Bio's technology evaluates a patient's genome at the point of care and distills it, providing physicians with concise, actionable reports that allow for more informed decisions, and the partners will seek to unlock the potential of next-generation sequencing and make these technologies available for all patients.

 

"In our laboratories, we are rapidly adopting and implementing next-generation sequencing as a platform upon which we will be providing cutting-edge genome-based testing," Franklin Cockerill, M.D., president of Mayo Medical Laboratories, noted in a press release. "This collaboration with SV Bio furthers our mission of bringing the latest diagnostic technologies to health care providers around the world."  

 

"We are now able to take data from any next-generation sequencer and determine with clinical-grade sensitivity and specificity which variants within a patient's DNA sequence are influencing a disease or condition, and rapidly provide a report for the clinician that is clear and actionable," said Stephan. "This level of speed, accuracy and integration into the clinical work flow is not only a first for molecular testing, but also a sea change in the application of next-generation sequencing with no compromise of quality in clinical diagnostics."    

 

 

SOURCE: SV Bio press release